THALES
Thales, the leading global technology and security provider, today announced the launch of CipherTrust Cloud Key Management's Hold Your Own Key (HYOK) in Oracle Cloud Infrastructure (OCI) across all 45 Oracle Cloud Regions—including the recently launched Oracle EU Sovereign Cloud—and OCI’s other distributed cloud offerings. To help meet continued customer demand and the accelerated growth of the OCI platform, HYOK will help OCI customers achieve their data sovereignty and other compliance objectives more easily by encrypting data in OCI with keys that are controlled and managed outside of the cloud platform. The new HYOK capabilities expand on existing support for Bring Your Own Key (BYOK) in OCI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918263668/en/
©Thales
According to the 2023 Thales Cloud Security Study, while the world has become cloud-first, operational complexity in cloud environments remains a significant obstacle for organizations. Overall, cloud security awareness has improved, but concerns around securing data are also rising, with over half (55 percent) of security professionals indicating it’s more complex to manage data in the cloud than it is in on-premises environments. As a result, as cloud usage grows, organizations need a new way to effectively secure cloud environments.
The CipherTrust Cloud Key Management integration enables OCI customers to store and manage their encryption keys outside OCI in a virtual or physical appliance that is entirely under their control and outside of the cloud. Customers can also localize their encryption keys wherever they choose and maintain control of their encrypted data in cloud environments. This approach helps address some of the key privacy and data sovereignty requirements organizations face while making it easier to demonstrate compliance to regulators.
The availability of the Thales external key management solution can help accelerate the move of sensitive data into Oracle Cloud Regions by storing the key in a location that is different than the encrypted data. This enables customers to maintain the same process for managing and controlling encryption keys, whether those keys are used on-premises or in the cloud
Thales CipherTrust Cloud Key Management, the industry-leading multi-cloud encryption key lifecycle management solution, alleviates operational barriers across clouds and hybrid environments. The HYOK functionality gives OCI customers the external key management capabilities necessary to navigate today’s cloud-driven landscape and remain in charge of their data, not just in OCI, but across other cloud providers.
Todd Moore, Vice President of Data Security Products at Thales: “Businesses are increasingly shifting away from legacy on-premises deployments and need assistance in moving their data to the cloud while maintaining security and compliance. As the industry leader in external key management, we’re proud to be the first to support HYOK features in OCI, equipping OCI customers with the necessary solutions to be successful in this journey. To further this best-in-class experience for our combined customer base, Thales is also the first supporting vendor for Oracle EU Sovereign Cloud initiatives.”
Jeppe Larsen, Senior Vice President, OCI Security and Identity at Oracle: “We’re dedicated to making OCI the most trusted cloud for security-sensitive workloads, including those in highly regulated regions and industries. Oracle EU Sovereign Cloud helps customers operating in Europe to address their data sovereignty requirements, and the HYOK integration with Thales enhances that offering. In addition, this partnership and integration will benefit U.S. customers in regulated industries such as financial services by enabling them to take full advantage of OCI, with the privacy and security benefits of HYOK from Thales.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion. |
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918263668/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom